Shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) saw an uptick in trading volume on Thursday . 911,219 shares changed hands during trading, an increase of 799% from the previous session’s volume of 101,338 shares.The stock last traded at $4.33 and had previously closed at $4.04.

A number of brokerages have issued reports on AGTC. HC Wainwright reaffirmed a “buy” rating and set a $5.75 target price on shares of Applied Genetic Technologies in a research report on Friday, February 8th. BMO Capital Markets cut Applied Genetic Technologies from an “outperform” rating to a “market perform” rating and set a $5.00 target price for the company. in a research report on Thursday, December 13th. ValuEngine cut Applied Genetic Technologies from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 5th. TheStreet cut Applied Genetic Technologies from a “c-” rating to a “d+” rating in a research report on Wednesday, January 2nd. Finally, Zacks Investment Research raised Applied Genetic Technologies from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Tuesday, February 12th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $6.90.

The stock has a market cap of $72.50 million, a price-to-earnings ratio of -3.67 and a beta of 2.85.

Applied Genetic Technologies (NASDAQ:AGTC) last posted its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.41. Applied Genetic Technologies had a negative return on equity of 19.73% and a negative net margin of 61.04%. The company had revenue of $5.93 million during the quarter. Analysts anticipate that Applied Genetic Technologies Corp will post -1.25 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Alambic Investment Management L.P. boosted its position in shares of Applied Genetic Technologies by 96.0% in the fourth quarter. Alambic Investment Management L.P. now owns 47,600 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 23,309 shares during the period. Two Sigma Advisers LP boosted its position in shares of Applied Genetic Technologies by 153.8% in the fourth quarter. Two Sigma Advisers LP now owns 80,729 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 48,922 shares during the period. Geode Capital Management LLC boosted its position in shares of Applied Genetic Technologies by 15.2% in the fourth quarter. Geode Capital Management LLC now owns 82,686 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 10,909 shares during the period. Two Sigma Investments LP boosted its position in shares of Applied Genetic Technologies by 64.9% in the fourth quarter. Two Sigma Investments LP now owns 206,522 shares of the biotechnology company’s stock valued at $514,000 after acquiring an additional 81,250 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Applied Genetic Technologies by 9,001.3% in the third quarter. Wells Fargo & Company MN now owns 215,610 shares of the biotechnology company’s stock valued at $1,574,000 after acquiring an additional 213,241 shares during the period. 43.04% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://theolympiareport.com/2019/03/14/applied-genetic-technologies-agtc-sees-unusually-high-trading-volume.html.

Applied Genetic Technologies Company Profile (NASDAQ:AGTC)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

Featured Story: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.